Prepare for NEET Biology Biotechnology and Its Applications with MCQs & PYQs on NEET.GUIDE. Access free practice, previous year questions, and expert help to master biotech concepts.
NEET Questions / Botany / Biotechnology and Its Applications
A patient exhibits severe combined immunodeficiency (SCID) due to a deficiency in adenosine deaminase (ADA). Which gene therapy approach is MOST likely to provide a long-term solution?
In vivo gene therapy using a retroviral vector directly injected into the bone marrow.
Administering purified ADA enzyme intravenously.
Ex vivo gene therapy using autologous hematopoietic stem cells.
Bone marrow transplant from an HLA-matched sibling.
In gene therapy for Adenosine Deaminase (ADA) deficiency, repeated infusions of genetically engineered lymphocytes are required because:
Genetically engineered lymphocytes are not immortal and are periodically destroyed.
The introduced ADA gene is gradually silenced in the engineered lymphocytes.
The patient's immune system rejects the genetically engineered lymphocytes.
The genetically engineered lymphocytes migrate to other tissues and lose their functionality.
Why do patients with ADA deficiency undergoing gene therapy need multiple infusions of modified lymphocytes?
The engineered lymphocytes have a limited lifespan.
The ADA gene integrates randomly and may become inactive.
The patient develops antibodies against the engineered lymphocytes.
The engineered lymphocytes fail to reach the target tissues.
Which of the following is the primary reason why gene therapy for ADA deficiency requires repeated lymphocyte infusions?
Limited lifespan of the modified lymphocytes.
Immune rejection of the modified lymphocytes.
Loss of ADA gene expression over time.
Inability of the modified lymphocytes to produce functional ADA.
A child with ADA deficiency is undergoing gene therapy. Why are repeated infusions of genetically corrected lymphocytes necessary?
The modified lymphocytes have a finite lifespan.
The ADA gene is unstable and frequently mutates.
The child's body rejects the modified lymphocytes.
The modified lymphocytes cannot produce sufficient ADA.
In ADA deficiency gene therapy, if the genetically modified lymphocytes were able to self-renew indefinitely, would periodic infusions still be necessary? Explain your reasoning.
No, because self-renewing lymphocytes would provide a continuous source of ADA.
Yes, because the ADA gene might still be silenced over time.
Yes, because the immune system might eventually reject the modified lymphocytes.
Yes, because the modified lymphocytes might lose their ability to produce ADA.
Which type of vector is used to introduce a functional ADA cDNA into lymphocytes, in gene therapy for ADA deficiency?
Plasmid
Bacteriophage
BAC
Retrovirus
When a person with defective Adenosine Deaminase (ADA) was treated, which of the following steps were performing for gene therapy?
I. Lymphocytes were extracted from the bone marrow of the patient
II. Lymphocytes were grown in a culture out side the body
III. Lymphocytes were transfected with the normal ADA genes
IV. The transfected cells were returned to the patients
I, II and III
I, III and IV
II, III and IV
I, II, III and IV
Which kind of therapy was given in 1990 to a four-year-old girl with adenosine deaminase (ADA) deficiency?
Radiation therapy
Gene therapy
Chemotherapy
Immunotherapy
